Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of Clear Cell Renal Cell Carcinoma
NCT05172440Phase 2Unknown
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in clear cell renal cell carcinoma (ccRCC). Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05172440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172440.